Compare ACCO & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACCO | GALT |
|---|---|---|
| Founded | 1893 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Publishing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 353.3M | 297.0M |
| IPO Year | 2005 | 2008 |
| Metric | ACCO | GALT |
|---|---|---|
| Price | $4.24 | $3.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $5.00 | ★ $8.50 |
| AVG Volume (30 Days) | ★ 626.2K | 354.3K |
| Earning Date | 04-30-2026 | 05-15-2026 |
| Dividend Yield | ★ 9.26% | N/A |
| EPS Growth | ★ 141.51 | 36.84 |
| EPS | ★ 0.35 | N/A |
| Revenue | ★ $1,524,700,000.00 | N/A |
| Revenue This Year | $3.10 | N/A |
| Revenue Next Year | $0.89 | N/A |
| P/E Ratio | $12.09 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.81 | $2.03 |
| 52 Week High | $4.56 | $7.13 |
| Indicator | ACCO | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 50.47 | 54.44 |
| Support Level | $4.22 | $3.53 |
| Resistance Level | $4.33 | $4.35 |
| Average True Range (ATR) | 0.11 | 0.26 |
| MACD | -0.02 | 0.06 |
| Stochastic Oscillator | 18.64 | 92.82 |
ACCO Brands Corp is a consumer, technology and business branded products company providing brands and product solutions used in schools, homes and at work. Its brands include At-A-Glance, Barrilito, Buro, Esselte, Five Star, Foroni, GBC, Hilroy, Kensington, Leitz, Mead, PowerA, Quartet, Rapid, Swingline and Tilibra. The Company's product categories include gaming and computer accessories, storage and organization, notebooks, shredding, laminating and binding machines, dry erase boards and do-it-yourself tools. The Company operates through two segments, Americas and International. Americas includes the U.S., Canada, Brazil, Mexico and Chile, and International includes EMEA, Australia, New Zealand and Asia. Its products are sold in the U.S., Europe, Australia, Canada, Brazil and Mexico.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.